{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:48:03Z","timestamp":1790725683964,"version":"4.1.0"},"reference-count":70,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>VEXAS (vacuoles, E1 enzyme, X linked, autoinflammatory, somatic) syndrome is a clonal hematoinflammatory disorder affecting older, predominantly male patients, characterized by systemic inflammation and progressive bone marrow failure. It is caused by somatic mutations in ubiquitin-activating enzyme E1 (UBA1), an X-linked gene, essential for initiating cellular ubiquitination. Loss-of-function mutations, most commonly M41 missense variants, lead to decreased expression of the cytoplasmic isoform, UBA1b, resulting in accumulation of misfolded proteins and activation of the endoplasmic reticulum stress pathway. Patients classically present with systemic and often refractory inflammation, requiring chronic glucocorticoid treatment and targeted immunosuppressive therapies. A central hallmark of this syndrome is progressive bone marrow failure and associated cytopenia, with a diagnosis of myelodysplastic syndromes (MDS) being reported in \u223c30% to 50% of patients, whereas only 1% of unselected patients with MDS have UBA1 mutations. This review examines current literature on distinct MDS features reported in VEXAS syndrome. We first summarize the defects and alterations in the hematopoietic system from UBA1 mutations, including associated peripheral blood and bone marrow findings. Next, we describe the histologic and molecular characteristics of patients with VEXAS syndrome, with and without MDS, and review potential treatment strategies, including responses to hypomethylating agents. Finally, we highlight that VEXAS-associated MDS is a challenging diagnosis but one with unique clinical, laboratory, and morphologic features, including prognostic implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018827","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:02:12Z","timestamp":1781301732000},"page":"5951-5961","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Myelodysplasia in VEXAS syndrome"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2974-7701","authenticated-orcid":false,"given":"Bhavisha A.","family":"Patel","sequence":"first","affiliation":[{"name":"1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-4191","authenticated-orcid":false,"given":"Katherine R.","family":"Calvo","sequence":"additional","affiliation":[{"name":"2Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaren K.","family":"Reichard","sequence":"additional","affiliation":[{"name":"3Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"27","key":"2026090811321795500_bib1","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2026090811321795500_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.18632\/oncotarget.28646","article-title":"UBA1 dysfunction in VEXAS and cancer","volume":"15","author":"Sakuma","year":"2024","journal-title":"Oncotarget"},{"issue":"16","key":"2026090811321795500_bib3","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.2024028216","article-title":"Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome","volume":"146","author":"Breillat","year":"2025","journal-title":"Blood"},{"key":"2026090811321795500_bib4","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.19.594376","article-title":"Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome","author":"Ganesan","year":"20  2024","journal-title":"bioRxiv"},{"issue":"13","key":"2026090811321795500_bib5","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"key":"2026090811321795500_bib6","doi-asserted-by":"crossref","first-page":"103354","DOI":"10.1016\/j.eclinm.2025.103354","article-title":"Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review","volume":"86","author":"Efficace","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"suppl 1","key":"2026090811321795500_bib7","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2024-205755","article-title":"Patient reported outcomes in VEXAS syndrome","volume":"144","author":"Patel","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026090811321795500_bib8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"2026090811321795500_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population","volume":"329","author":"Beck","year":"2023","journal-title":"Jama"},{"issue":"6","key":"2026090811321795500_bib10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/art.42802","article-title":"VEXAS-defining UBA1 somatic variants in 245,368 diverse individuals in the NIH all of US cohort","volume":"76","author":"Corty","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"16","key":"2026090811321795500_bib11","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2026090811321795500_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/ajcp\/aqad186","article-title":"Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: a single-institution longitudinal study of 111 bone marrow samples from 52 patients","volume":"161","author":"Olteanu","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"2026090811321795500_bib13","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.mayocp.2021.06.006","article-title":"Clinical heterogeneity of the VEXAS syndrome: a case series","volume":"96","author":"Koster","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2026090811321795500_bib14","first-page":"244","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026090811321795500_bib15","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood.2023023723","article-title":"Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes","volume":"144","author":"Sirenko","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026090811321795500_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/hematology.2021000246","article-title":"When to worry about inherited bone marrow failure and myeloid malignancy predisposition syndromes in the setting of a hypocellular marrow","volume":"2021","author":"Narla","year":"2021","journal-title":"Hematology"},{"issue":"4","key":"2026090811321795500_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2021.09.001","article-title":"Toward a pathophysiology inspired treatment of VEXAS syndrome","volume":"58","author":"Heiblig","year":"2021","journal-title":"Semin Hematol"},{"issue":"3","key":"2026090811321795500_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/art.43287","article-title":"American College of Rheumatology guidance statement for diagnosis and management of VEXAS developed by the International VEXAS Working Group expert panel","volume":"78","author":"Mekinian","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2026090811321795500_bib19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ard.2025.05.021","article-title":"Disease trajectories and glucocorticoid exposure in VEXAS syndrome treated with cytokine-directed therapies","volume":"85","author":"Turturice","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2026090811321795500_bib20","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood.2024028133","article-title":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX","volume":"146","author":"Jachiet","year":"2025","journal-title":"Blood"},{"issue":"10","key":"2026090811321795500_bib21","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3324\/haematol.2024.285519","article-title":"De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine","volume":"109","author":"Trikha","year":"2024","journal-title":"Haematologica"},{"issue":"6","key":"2026090811321795500_bib22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","article-title":"Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT","volume":"8","author":"Gurnari","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026090811321795500_bib23","first-page":"S292","article-title":"Pilot prospective study of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with Vexas syndrome","volume":"30","author":"Mangaonkar","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"2026090811321795500_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","article-title":"Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies","volume":"37","author":"Sakuma","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"2026090811321795500_bib25","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1097\/HS9.0000000000000868","article-title":"Recurrent mutations of the active adenylation domain of UBA1 in atypical form of VEXAS syndrome","volume":"7","author":"Faurel","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"2026090811321795500_bib26","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s44318-024-00046-z","article-title":"Shared and distinct mechanisms of UBA1 inactivation across different diseases","volume":"43","author":"Collins","year":"2024","journal-title":"EMBO J"},{"issue":"2","key":"2026090811321795500_bib27","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/kead472","article-title":"Three UBA1 clones for a unique VEXAS syndrome","volume":"63","author":"Podvin","year":"2024","journal-title":"Rheumatology"},{"issue":"8","key":"2026090811321795500_bib28","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.xcrm.2023.101160","article-title":"Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"2026090811321795500_bib29","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation","volume":"15","author":"Kosmider","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"2026090811321795500_bib30","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41591-025-03623-9","article-title":"Mechanisms of hematopoietic clonal dominance in VEXAS syndrome","volume":"31","author":"Molteni","year":"2025","journal-title":"Nat Med"},{"issue":"24","key":"2026090811321795500_bib31","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1182\/bloodadvances.2023010531","article-title":"Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome","volume":"7","author":"Chiaramida","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2026090811321795500_bib32","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.2025029081","article-title":"VEXAS syndrome anemia is a mosaic erythroblastopenia","volume":"147","author":"Rodrigues","year":"2026","journal-title":"Blood"},{"issue":"suppl 9","key":"2026090811321795500_bib33","article-title":"IDH1\/2 somatic hotspot mutations as independent drivers of autoinflammation [abstract]","volume":"77","author":"Castellan","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2026090811321795500_bib34","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1038\/s41467-025-59890-0","article-title":"In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome","volume":"16","author":"Mizumaki","year":"2025","journal-title":"Nat Commun"},{"issue":"7","key":"2026090811321795500_bib35","doi-asserted-by":"crossref","first-page":"ofae405","DOI":"10.1093\/ofid\/ofae405","article-title":"Opportunistic infections, mortality risk, and prevention strategies in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome","volume":"11","author":"Czech","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"2026090811321795500_bib36","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1016\/S2665-9913(25)00225-5","article-title":"Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention","volume":"7","author":"Ribier","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"2026090811321795500_bib37","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/ajh.26931","article-title":"Peripheral blood cells vacuoles in VEXAS syndrome","volume":"98","author":"Tosato","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"2026090811321795500_bib38","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(23)00375-7","article-title":"Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond","volume":"11","author":"Lacombe","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026090811321795500_bib39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.17679","article-title":"Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold","volume":"195","author":"Lacombe","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2026090811321795500_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ijlh.14368","article-title":"Deep learning-based blood abnormalities detection as a tool for VEXAS syndrome screening","volume":"47","author":"De Almeida Braga","year":"2025","journal-title":"Int J Lab Hematol"},{"key":"2026090811321795500_bib41","doi-asserted-by":"crossref","first-page":"1466720","DOI":"10.3389\/fimmu.2024.1466720","article-title":"Expanding the VEXAS diagnostic workup: the role of peripheral blood cytological analysis","volume":"15","author":"Baggio","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"2026090811321795500_bib42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.seminhematol.2021.10.007","article-title":"Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome","volume":"58","author":"Patel","year":"2021","journal-title":"Semin Hematol"},{"issue":"26","key":"2026090811321795500_bib43","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood.2021010811","article-title":"Vacuolization of hematopoietic precursors: an enigma with multiple etiologies","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026090811321795500_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/ejh.13944","article-title":"VEXAS syndrome: a review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation","volume":"110","author":"Cherniawsky","year":"2023","journal-title":"Eur J Haematol"},{"key":"2026090811321795500_bib45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-pathmechdis-051222-122724","article-title":"Clonal hematopoiesis, inflammation, and hematologic malignancy","volume":"19","author":"Kanagal-Shamanna","year":"2024","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"2026090811321795500_bib46","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026090811321795500_bib47","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"2026090811321795500_bib48","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"2026090811321795500_bib49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-012-0140-3","article-title":"Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors","volume":"7","author":"Steensma","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"2026090811321795500_bib50","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3324\/haematol.2017.167726","article-title":"Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation","volume":"102","author":"Kanagal-Shamanna","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"2026090811321795500_bib51","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/asheducation-2011.1.525","article-title":"Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation","volume":"2011","author":"Fleming","year":"2011","journal-title":"Hematology"},{"issue":"9","key":"2026090811321795500_bib52","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2026090811321795500_bib53","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2026090811321795500_bib54","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41375-025-02858-2","article-title":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome","volume":"40","author":"Zhao","year":"2026","journal-title":"Leukemia"},{"issue":"2","key":"2026090811321795500_bib55","first-page":"103386","article-title":"New scenarios in vacuoles, E1 enzyme, X linked, autoinflammatory, somatic (VEXAS) syndrome: evolution from myelodysplastic syndrome to acute myeloid leukemia","volume":"71","author":"Battipaglia","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"3","key":"2026090811321795500_bib56","doi-asserted-by":"crossref","first-page":"e259474","DOI":"10.1136\/bcr-2023-259474","article-title":"VEXAS syndrome presenting as diffuse alveolar haemorrhage","volume":"17","author":"Sofi","year":"2024","journal-title":"BMJ Case Rep"},{"key":"2026090811321795500_bib57","doi-asserted-by":"crossref","first-page":"1354130","DOI":"10.3389\/fimmu.2024.1354130","article-title":"Case report: cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort","volume":"15","author":"Diral","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"2026090811321795500_bib58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00428-022-03447-9","article-title":"The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia","volume":"482","author":"Rudelius","year":"2023","journal-title":"Virchows Arch"},{"issue":"12","key":"2026090811321795500_bib59","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood.2025029732","article-title":"Azacitidine as therapy for VEXAS syndrome","volume":"146","author":"Steensma","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026090811321795500_bib60","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","article-title":"A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","volume":"36","author":"Mekinian","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2026090811321795500_bib61","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1002\/hem3.129","article-title":"Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome","volume":"8","author":"Aalbers","year":"2024","journal-title":"Hemasphere"},{"issue":"3","key":"2026090811321795500_bib62","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-023-05611-w","article-title":"VEXAS syndrome: complete molecular remission after hypomethylating therapy","volume":"103","author":"Sockel","year":"2024","journal-title":"Ann Hematol"},{"issue":"10","key":"2026090811321795500_bib63","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/ard-2024-225640","article-title":"Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX","volume":"83","author":"Hadjadj","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2026090811321795500_bib64","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12185-023-03598-8","article-title":"Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome","volume":"118","author":"Kunimoto","year":"2023","journal-title":"Int J Hematol"},{"issue":"6","key":"2026090811321795500_bib65","doi-asserted-by":"crossref","first-page":"e70156","DOI":"10.1002\/hem3.70156","article-title":"Efficacy of erythroid-stimulating agent and luspatercept in VEXAS syndrome: a multicenter retrospective study by the FRENVEX group","volume":"9","author":"Heiblig","year":"2025","journal-title":"Hemasphere"},{"issue":"3","key":"2026090811321795500_bib66","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood.2023020772","article-title":"VEXAS: walking on the edge of malignancy","volume":"142","author":"Malcovati","year":"2023","journal-title":"Blood"},{"key":"2026090811321795500_bib67","doi-asserted-by":"crossref","first-page":"897722","DOI":"10.3389\/fimmu.2022.897722","article-title":"Case report: coexistence of multiple myeloma and auricular chondritis in VEXAS syndrome","volume":"13","author":"Matsumoto","year":"2022","journal-title":"Front Immunol"},{"issue":"22","key":"2026090811321795500_bib68","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1182\/bloodadvances.2023010814","article-title":"Intrapatient competition of VEXAS syndrome and CML clones","volume":"7","author":"Djerbi","year":"2023","journal-title":"Blood Adv"},{"key":"2026090811321795500_bib69","first-page":"6551544","article-title":"VEXAS syndrome in a patient with myeloproliferative neoplasia","volume":"2023","author":"Austestad","year":"2023","journal-title":"Case Rep Hematol"},{"issue":"12","key":"2026090811321795500_bib70","doi-asserted-by":"crossref","first-page":"e251089","DOI":"10.1136\/bcr-2022-251089","article-title":"VEXAS syndrome with progression of MDS to MDS\/MPN overlap syndrome","volume":"15","author":"Neupane","year":"2022","journal-title":"BMJ Case Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5951\/2541849\/blooda_adv-2025-018827-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5951\/2541849\/blooda_adv-2025-018827-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:27Z","timestamp":1788881547000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5951\/569116\/Myelodysplasia-in-VEXAS-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":70,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018827","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}